Analyst Insights

Roth Capital Reiterated Buy On Regeneron Following EU Approval Of Eylea

Regeneron Pharmaceuticals (REGN) announced that Eylea has been approved by the European Commission for use in patients with DME. Marketing of Eylea will be initiated …

Roth Capital Reiterates Buy On Peregrine Following New Preclinical Data

In a research note published August 11, Roth Capital analyst Joseph Pantginis issued a note in which he reiterated a Buy rating on Peregrine Pharmaceuticals (PPHM) with …

Maxim Reaffirms Buy On Inovio Pharmaceuticals Following 2Q14 Update

In a research note released August 11, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Inovio Pharmaceuticals (INO) with an $18 price target, following the company’s second-quarter results. Inovio …

H.C. Wainwright Reiterates Buy On PharmAthene Following Court Victory Against SIGA

PharmAthene (PIP) announced this weekend, that on Friday, the Delaware Court of Chancery issued a Memorandum Opinion awarding PharmAthene lump sum expectation damages …

We Continue To View URRE As An Asset Value Play, Says Roth Capital

In a research note released August 11, Roth Capital analyst Joe Reagor maintained a Buy rating on Uranium Resources (URRE) with a $4.00 price target, following the company’s second-quarter earnings.

Roth Capital Maintains Bullish Stance On CDTi Following Second Quarter Earnings Results

In a research report published August 11, Roth Capital analyst Matt Koranda maintained a Buy rating on Clean Diesel Technologies (CDTI) and a $3.75 price target.

Nuverra Quarterly Update; Roth Capital Reiterates Buy

In a research report released August 11, Roth Capital analyst Philip Shen reiterated coverage with a Buy rating on Nuverra (NES) with a $20 price target, following the company’s …

Shares Of Keryx Remain Undervalued And Represent Upside, Says H.C. Wainwright

In a research note published August 8, H.C.

Roth Capital Reiterates Buy On Spectrum Pharmaceuticals Following 2Q14 Results

In a research note published August 8, Roth Capital analyst Joseph Pantginis issued a note in which he reiterated a Buy rating on Spectrum …

The SolarCity Machine Is Well In Place To Aggressively Grow, Says Roth Capital

In a research report published August 8, Roth Capital analyst Philip Shen reiterated a Buy rating on SolarCity Corp. (SCTY) and increased his …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts